Open Access Research Article Article ID: ACMPH-5-152

    Immunological outcomes between Tenofovir versus Zidovudine-based regimens: a retrospective cohort study

    Meshack Lugoba1, Manase Kilonzi1, George M Bwire2*, Pacifi que Ndayishimiye1, Wigilya P Mikomangwa1, Hamu J Mlyuka1, Alphonce I Marealle1, Ritah F Mutagonda1 and Kennedy D Mwambete2

    Background: Since 2013, Tenofovir (TDF) and Zidovudine (AZT) based regimen are alternatively used as a fi rst line for treatment of HIV in Tanzania. CD4+ cells count, which is recommended after every six months monitors the immunological progression, and used as one of the indicators of treatment progression. However, there is little literature available information to compare the immunological outcomes of these two regimens.

    Methods: A hospital-based retrospective cohort study was conducted at Muhimbili National Hospital, Care and Treatment Clinic (MNH-CTC) in Dar es Salaam. HIV/AIDS patients’ fi les of October 2012 through November 2016 were reviewed. Using statistical package for social sciences (SPSS version 23), the mean CD4+ cells count were compared by independent t-test while Chi-square test was performed to associate categorical variables. Binary logistic regression was used to control variables such as sex and body mass index (BMI). The results were considered having statistical signifi cance when the P 0.05.


    Published on: Jul 11, 2019 Pages: 43-48

    Full Text PDF Full Text HTML DOI: 10.17352/2455-5479.000052
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on ACMPH